Compare Open Text Corporation (OTEX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Open Text Corporation vs TG Therapeutics Inc — how do they compare? Open Text Corporation trades at $23.7 (market cap $5.61B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Open Text Corporation pays a 4.82% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Open Text Corporation for 23 Days and TG Therapeutics Inc for 16 Days on average.
| OTEX | TGTX | |
|---|---|---|
Market Cap | $5.61B | $8.16B |
Volume | 1,197,475 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $39.69 | $59.06 |
52-Week Low | $20.01 | $26.94 |
Typical Hold Time | 23 Days | 16 Days |
Enterprise Value | $10.63B | $8.37B |
Dividend Yield | 4.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OpenText (OTEX) trades at $23.24, up 0.43% with a bearish technical signal despite strong fundamentals. The company shows robust profitability with 73.74% gross margins and consistent earnings beats, while actively managing debt through recent $1 billion notes offering. Valuation appears attractive with P/E of 9.01 and P/S of 1.1, trading below analyst consensus target of $28.30.
The stock presents value opportunity with discounted multiples and improving cloud momentum, though technical weakness and debt refinancing activities warrant caution. Upside potential exists if earnings growth continues, while execution risks and market sentiment remain key watchpoints for investors.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
